VRDN – viridian therapeutics, inc. (US:NASDAQ)
Stock Stats
News
Viridian Therapeutics (NASDAQ:VRDN) was upgraded by analysts at UBS Group AG to a "strong-buy" rating.
Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Viridian Therapeutics (NASDAQ:VRDN) had its price target lowered by analysts at Truist Financial Corporation from $41.00 to $40.00. They now have a "buy" rating on the stock.
Viridian Therapeutics (NASDAQ:VRDN) is now covered by analysts at UBS Group AG. They set a "buy" rating on the stock.
Viridian Therapeutics Prepares for Transformational 2026 [Yahoo! Finance]
Form 4 Viridian Therapeutics, For: Dec 31 Filed by: Tousignant Jennifer
Form 144 Viridian Therapeutics, Filed by: Tousignant Jennifer
Form SCHEDULE 13G/A Viridian Therapeutics, Filed by: Commodore Capital LP
Form 10-Q Viridian Therapeutics, For: Sep 30
Form 8-K Viridian Therapeutics, For: Nov 05
Top News Gainers
Top News Decliners
Live Event: How Top Hedge Funds Use News To Make Money From The Stock Market & How Ordinary People Are Copying Their Strategies
If you could use the news to make money from the stock market, would you? Join us on our live online event where you’ll discover this simple scientific method that has allowed ordinary people get a huge return from the stock market without excessive risk.